Loading…
Inhibition of friend leukemia cell visceral metastases by a new monoclonal antibody and role of the immune system of the host in its action
We developed a syngeneic mouse IgG2a monoclonal antibody (MAb) A9D41 directed against the Friend leukemia virus envelope gp70 antigen present on the cell surface membranes of virus producer 3C18 Friend leukemia cells (FLC). A9D41 showed a marked antitumor activity in DBA/2 mice given injections of g...
Saved in:
Published in: | Cancer research (Chicago, Ill.) Ill.), 1992-05, Vol.52 (10), p.2880-2889 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 2889 |
container_issue | 10 |
container_start_page | 2880 |
container_title | Cancer research (Chicago, Ill.) |
container_volume | 52 |
creator | SALA, A GRESSER, I CHASSOUX, D.D MAURY, C SANTODONATO, L EID, P MAUNOURY, M.-T BARCA, SS CIANFRIGLIA, M BELARDELLI, F |
description | We developed a syngeneic mouse IgG2a monoclonal antibody (MAb) A9D41 directed against the Friend leukemia virus envelope gp70 antigen present on the cell surface membranes of virus producer 3C18 Friend leukemia cells (FLC). A9D41 showed a marked antitumor activity in DBA/2 mice given injections of gp70 positive 3C18 FLC, but it was ineffective in mice given injections of gp70 negative 745 FLC or unrelated tumor cells. A9D41 was particularly effective in inhibiting the development of 3C18 FLC liver and spleen metastases. MAb was also effective as adjuvant therapy in inhibiting visceral metastases after excision of an established s.c. FLC tumor, and combined therapy of A9D41 with mouse interferon alpha/beta was more effective than MAb or interferon alpha/beta alone. The immune system of the host played a decisive role in the antimetastatic action of A9D41. Thus, although MAb was cytotoxic for 3C18 FLC in vitro in the presence of rabbit complement, the F(ab')2 fragment was ineffective in vivo, and the antitumor effect of MAb was abolished in mice treated with an antibody to CD4 and diminished in natural killer cell-deficient beige and athymic nude mice. MAb-treated mice surviving injection of FLC developed an immune response to 3C18 FLC. |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_72933730</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72933730</sourcerecordid><originalsourceid>FETCH-LOGICAL-h271t-3c72fad4574913b22d86a1c3a45ef6b383b852b4563f9ceeea38bdbe12afc8f43</originalsourceid><addsrcrecordid>eNo9kN1KxDAQhYso67r6CEIuxLtCkzRt91IWfxYWvNHrMkknNJqftUmVfQZf2i5WYWCY-Q6HM3OSLangTV6XpTjNlkVRNLkoa3aeXcT4No2CFmKRLaho6Lrgy-x763sjTTLBk6CJHgz6jlgc39EZIAqtJZ8mKhzAEocJ4lQYiTwQIB6_iAs-KBv8hMEnI0M3kcliCBaPjqlHYpwbPZJ4iAnd37IPMRHjiUmRgDoGuMzONNiIV3NfZa8P9y-bp3z3_Ljd3O3yntU05VzVTENXirpcUy4Z65oKqOJQCtSV5A2XjWCyFBXXa4WIwBvZSaQMtGp0yVfZ7a_vfggfI8bUuuOF1oLHMMa2ZmvOa15MwutZOEqHXbsfjIPh0M7fm_jNzCEqsHoAr0z8lwnOBK0q_gP3g3vN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72933730</pqid></control><display><type>article</type><title>Inhibition of friend leukemia cell visceral metastases by a new monoclonal antibody and role of the immune system of the host in its action</title><source>EZB Electronic Journals Library</source><creator>SALA, A ; GRESSER, I ; CHASSOUX, D.D ; MAURY, C ; SANTODONATO, L ; EID, P ; MAUNOURY, M.-T ; BARCA, SS ; CIANFRIGLIA, M ; BELARDELLI, F</creator><creatorcontrib>SALA, A ; GRESSER, I ; CHASSOUX, D.D ; MAURY, C ; SANTODONATO, L ; EID, P ; MAUNOURY, M.-T ; BARCA, SS ; CIANFRIGLIA, M ; BELARDELLI, F</creatorcontrib><description>We developed a syngeneic mouse IgG2a monoclonal antibody (MAb) A9D41 directed against the Friend leukemia virus envelope gp70 antigen present on the cell surface membranes of virus producer 3C18 Friend leukemia cells (FLC). A9D41 showed a marked antitumor activity in DBA/2 mice given injections of gp70 positive 3C18 FLC, but it was ineffective in mice given injections of gp70 negative 745 FLC or unrelated tumor cells. A9D41 was particularly effective in inhibiting the development of 3C18 FLC liver and spleen metastases. MAb was also effective as adjuvant therapy in inhibiting visceral metastases after excision of an established s.c. FLC tumor, and combined therapy of A9D41 with mouse interferon alpha/beta was more effective than MAb or interferon alpha/beta alone. The immune system of the host played a decisive role in the antimetastatic action of A9D41. Thus, although MAb was cytotoxic for 3C18 FLC in vitro in the presence of rabbit complement, the F(ab')2 fragment was ineffective in vivo, and the antitumor effect of MAb was abolished in mice treated with an antibody to CD4 and diminished in natural killer cell-deficient beige and athymic nude mice. MAb-treated mice surviving injection of FLC developed an immune response to 3C18 FLC.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>PMID: 1581903</identifier><identifier>CODEN: CNREA8</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Animals ; Antibodies, Monoclonal - therapeutic use ; Antibody Formation - immunology ; Antigens, Neoplasm - immunology ; Antigens, Surface - immunology ; Antineoplastic agents ; Biological and medical sciences ; Cell Division - physiology ; Combined Modality Therapy ; Complement System Proteins - immunology ; Cytotoxicity, Immunologic ; Friend murine leukemia virus - immunology ; Immunotherapy ; Injections, Intravenous ; Interferon-alpha - pharmacology ; Interferon-beta - pharmacology ; Leukemia, Erythroblastic, Acute - immunology ; Leukemia, Erythroblastic, Acute - pathology ; Leukemia, Erythroblastic, Acute - therapy ; Liver Neoplasms - prevention & control ; Liver Neoplasms - secondary ; Male ; Medical sciences ; Mice ; Mice, Inbred DBA ; Neoplasm Metastasis - immunology ; Neoplasm Metastasis - prevention & control ; Neoplasm Transplantation ; Pharmacology. Drug treatments ; Splenic Neoplasms - prevention & control ; Splenic Neoplasms - secondary ; Tumor Cells, Cultured</subject><ispartof>Cancer research (Chicago, Ill.), 1992-05, Vol.52 (10), p.2880-2889</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5325166$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1581903$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SALA, A</creatorcontrib><creatorcontrib>GRESSER, I</creatorcontrib><creatorcontrib>CHASSOUX, D.D</creatorcontrib><creatorcontrib>MAURY, C</creatorcontrib><creatorcontrib>SANTODONATO, L</creatorcontrib><creatorcontrib>EID, P</creatorcontrib><creatorcontrib>MAUNOURY, M.-T</creatorcontrib><creatorcontrib>BARCA, SS</creatorcontrib><creatorcontrib>CIANFRIGLIA, M</creatorcontrib><creatorcontrib>BELARDELLI, F</creatorcontrib><title>Inhibition of friend leukemia cell visceral metastases by a new monoclonal antibody and role of the immune system of the host in its action</title><title>Cancer research (Chicago, Ill.)</title><addtitle>Cancer Res</addtitle><description>We developed a syngeneic mouse IgG2a monoclonal antibody (MAb) A9D41 directed against the Friend leukemia virus envelope gp70 antigen present on the cell surface membranes of virus producer 3C18 Friend leukemia cells (FLC). A9D41 showed a marked antitumor activity in DBA/2 mice given injections of gp70 positive 3C18 FLC, but it was ineffective in mice given injections of gp70 negative 745 FLC or unrelated tumor cells. A9D41 was particularly effective in inhibiting the development of 3C18 FLC liver and spleen metastases. MAb was also effective as adjuvant therapy in inhibiting visceral metastases after excision of an established s.c. FLC tumor, and combined therapy of A9D41 with mouse interferon alpha/beta was more effective than MAb or interferon alpha/beta alone. The immune system of the host played a decisive role in the antimetastatic action of A9D41. Thus, although MAb was cytotoxic for 3C18 FLC in vitro in the presence of rabbit complement, the F(ab')2 fragment was ineffective in vivo, and the antitumor effect of MAb was abolished in mice treated with an antibody to CD4 and diminished in natural killer cell-deficient beige and athymic nude mice. MAb-treated mice surviving injection of FLC developed an immune response to 3C18 FLC.</description><subject>Animals</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibody Formation - immunology</subject><subject>Antigens, Neoplasm - immunology</subject><subject>Antigens, Surface - immunology</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Cell Division - physiology</subject><subject>Combined Modality Therapy</subject><subject>Complement System Proteins - immunology</subject><subject>Cytotoxicity, Immunologic</subject><subject>Friend murine leukemia virus - immunology</subject><subject>Immunotherapy</subject><subject>Injections, Intravenous</subject><subject>Interferon-alpha - pharmacology</subject><subject>Interferon-beta - pharmacology</subject><subject>Leukemia, Erythroblastic, Acute - immunology</subject><subject>Leukemia, Erythroblastic, Acute - pathology</subject><subject>Leukemia, Erythroblastic, Acute - therapy</subject><subject>Liver Neoplasms - prevention & control</subject><subject>Liver Neoplasms - secondary</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred DBA</subject><subject>Neoplasm Metastasis - immunology</subject><subject>Neoplasm Metastasis - prevention & control</subject><subject>Neoplasm Transplantation</subject><subject>Pharmacology. Drug treatments</subject><subject>Splenic Neoplasms - prevention & control</subject><subject>Splenic Neoplasms - secondary</subject><subject>Tumor Cells, Cultured</subject><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><recordid>eNo9kN1KxDAQhYso67r6CEIuxLtCkzRt91IWfxYWvNHrMkknNJqftUmVfQZf2i5WYWCY-Q6HM3OSLangTV6XpTjNlkVRNLkoa3aeXcT4No2CFmKRLaho6Lrgy-x763sjTTLBk6CJHgz6jlgc39EZIAqtJZ8mKhzAEocJ4lQYiTwQIB6_iAs-KBv8hMEnI0M3kcliCBaPjqlHYpwbPZJ4iAnd37IPMRHjiUmRgDoGuMzONNiIV3NfZa8P9y-bp3z3_Ljd3O3yntU05VzVTENXirpcUy4Z65oKqOJQCtSV5A2XjWCyFBXXa4WIwBvZSaQMtGp0yVfZ7a_vfggfI8bUuuOF1oLHMMa2ZmvOa15MwutZOEqHXbsfjIPh0M7fm_jNzCEqsHoAr0z8lwnOBK0q_gP3g3vN</recordid><startdate>19920515</startdate><enddate>19920515</enddate><creator>SALA, A</creator><creator>GRESSER, I</creator><creator>CHASSOUX, D.D</creator><creator>MAURY, C</creator><creator>SANTODONATO, L</creator><creator>EID, P</creator><creator>MAUNOURY, M.-T</creator><creator>BARCA, SS</creator><creator>CIANFRIGLIA, M</creator><creator>BELARDELLI, F</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19920515</creationdate><title>Inhibition of friend leukemia cell visceral metastases by a new monoclonal antibody and role of the immune system of the host in its action</title><author>SALA, A ; GRESSER, I ; CHASSOUX, D.D ; MAURY, C ; SANTODONATO, L ; EID, P ; MAUNOURY, M.-T ; BARCA, SS ; CIANFRIGLIA, M ; BELARDELLI, F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h271t-3c72fad4574913b22d86a1c3a45ef6b383b852b4563f9ceeea38bdbe12afc8f43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Animals</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibody Formation - immunology</topic><topic>Antigens, Neoplasm - immunology</topic><topic>Antigens, Surface - immunology</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Cell Division - physiology</topic><topic>Combined Modality Therapy</topic><topic>Complement System Proteins - immunology</topic><topic>Cytotoxicity, Immunologic</topic><topic>Friend murine leukemia virus - immunology</topic><topic>Immunotherapy</topic><topic>Injections, Intravenous</topic><topic>Interferon-alpha - pharmacology</topic><topic>Interferon-beta - pharmacology</topic><topic>Leukemia, Erythroblastic, Acute - immunology</topic><topic>Leukemia, Erythroblastic, Acute - pathology</topic><topic>Leukemia, Erythroblastic, Acute - therapy</topic><topic>Liver Neoplasms - prevention & control</topic><topic>Liver Neoplasms - secondary</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred DBA</topic><topic>Neoplasm Metastasis - immunology</topic><topic>Neoplasm Metastasis - prevention & control</topic><topic>Neoplasm Transplantation</topic><topic>Pharmacology. Drug treatments</topic><topic>Splenic Neoplasms - prevention & control</topic><topic>Splenic Neoplasms - secondary</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SALA, A</creatorcontrib><creatorcontrib>GRESSER, I</creatorcontrib><creatorcontrib>CHASSOUX, D.D</creatorcontrib><creatorcontrib>MAURY, C</creatorcontrib><creatorcontrib>SANTODONATO, L</creatorcontrib><creatorcontrib>EID, P</creatorcontrib><creatorcontrib>MAUNOURY, M.-T</creatorcontrib><creatorcontrib>BARCA, SS</creatorcontrib><creatorcontrib>CIANFRIGLIA, M</creatorcontrib><creatorcontrib>BELARDELLI, F</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SALA, A</au><au>GRESSER, I</au><au>CHASSOUX, D.D</au><au>MAURY, C</au><au>SANTODONATO, L</au><au>EID, P</au><au>MAUNOURY, M.-T</au><au>BARCA, SS</au><au>CIANFRIGLIA, M</au><au>BELARDELLI, F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition of friend leukemia cell visceral metastases by a new monoclonal antibody and role of the immune system of the host in its action</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><addtitle>Cancer Res</addtitle><date>1992-05-15</date><risdate>1992</risdate><volume>52</volume><issue>10</issue><spage>2880</spage><epage>2889</epage><pages>2880-2889</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><coden>CNREA8</coden><abstract>We developed a syngeneic mouse IgG2a monoclonal antibody (MAb) A9D41 directed against the Friend leukemia virus envelope gp70 antigen present on the cell surface membranes of virus producer 3C18 Friend leukemia cells (FLC). A9D41 showed a marked antitumor activity in DBA/2 mice given injections of gp70 positive 3C18 FLC, but it was ineffective in mice given injections of gp70 negative 745 FLC or unrelated tumor cells. A9D41 was particularly effective in inhibiting the development of 3C18 FLC liver and spleen metastases. MAb was also effective as adjuvant therapy in inhibiting visceral metastases after excision of an established s.c. FLC tumor, and combined therapy of A9D41 with mouse interferon alpha/beta was more effective than MAb or interferon alpha/beta alone. The immune system of the host played a decisive role in the antimetastatic action of A9D41. Thus, although MAb was cytotoxic for 3C18 FLC in vitro in the presence of rabbit complement, the F(ab')2 fragment was ineffective in vivo, and the antitumor effect of MAb was abolished in mice treated with an antibody to CD4 and diminished in natural killer cell-deficient beige and athymic nude mice. MAb-treated mice surviving injection of FLC developed an immune response to 3C18 FLC.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>1581903</pmid><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0008-5472 |
ispartof | Cancer research (Chicago, Ill.), 1992-05, Vol.52 (10), p.2880-2889 |
issn | 0008-5472 1538-7445 |
language | eng |
recordid | cdi_proquest_miscellaneous_72933730 |
source | EZB Electronic Journals Library |
subjects | Animals Antibodies, Monoclonal - therapeutic use Antibody Formation - immunology Antigens, Neoplasm - immunology Antigens, Surface - immunology Antineoplastic agents Biological and medical sciences Cell Division - physiology Combined Modality Therapy Complement System Proteins - immunology Cytotoxicity, Immunologic Friend murine leukemia virus - immunology Immunotherapy Injections, Intravenous Interferon-alpha - pharmacology Interferon-beta - pharmacology Leukemia, Erythroblastic, Acute - immunology Leukemia, Erythroblastic, Acute - pathology Leukemia, Erythroblastic, Acute - therapy Liver Neoplasms - prevention & control Liver Neoplasms - secondary Male Medical sciences Mice Mice, Inbred DBA Neoplasm Metastasis - immunology Neoplasm Metastasis - prevention & control Neoplasm Transplantation Pharmacology. Drug treatments Splenic Neoplasms - prevention & control Splenic Neoplasms - secondary Tumor Cells, Cultured |
title | Inhibition of friend leukemia cell visceral metastases by a new monoclonal antibody and role of the immune system of the host in its action |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T19%3A22%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20of%20friend%20leukemia%20cell%20visceral%20metastases%20by%20a%20new%20monoclonal%20antibody%20and%20role%20of%20the%20immune%20system%20of%20the%20host%20in%20its%20action&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=SALA,%20A&rft.date=1992-05-15&rft.volume=52&rft.issue=10&rft.spage=2880&rft.epage=2889&rft.pages=2880-2889&rft.issn=0008-5472&rft.eissn=1538-7445&rft.coden=CNREA8&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E72933730%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-h271t-3c72fad4574913b22d86a1c3a45ef6b383b852b4563f9ceeea38bdbe12afc8f43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=72933730&rft_id=info:pmid/1581903&rfr_iscdi=true |